News for Adicet Bio, Inc. (ACET)

WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. ( HOWL), an innovative biopharmaceutical company pioneering the development of

**media[548365]**

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Julie Maltzman appointed as Chief Medical Officer of Adicet Bio, leading clinical development strategy for autoimmune and oncology pipeline.

Adicet Bio Inc. (ACET) experienced a significant stock price drop of 5.43%, trading at $0.965 per share with a volume of 279,487 shares and a turnover rate of 0

Adicet Bio Inc. (ACET) experienced a significant stock movement, dropping 5.45% to $1.04 per share. The trading volume reached 409,983 shares with a turnover ra

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio begins trial for innovative cancer therapy

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disea

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

FDA greenlights Adicet Bio's trial expansion for autoimmune diseases

Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.<

The marginal zone lymphoma pipeline possesses potential drugs in mid-stage developments to be launched in the near future. The total marginal zone lymphoma...

On Wednesday, 311 stocks hit new 52-week lows.

The DLBCL market has a diverse pipeline, with the emergence of novel classes such as bi-specific antibodies, cancer vaccines, and allogeneic CAR-Ts in the...

Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM, revenues increased 14%Full year 2022 revenues decreased 24% to $12.17... | February 3, 2023

Marginal Zone Lymphoma Pipeline constitutes 40+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies,...